Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q54712992

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@en

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@nl

type

Item

label

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@en

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@nl

prefLabel

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@en

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@nl

P1476

Effects of motexafin gadoliniu ...... chronic lymphocytic leukemia.

@en

P2093

Carolyn Cheney

http://www.w3.org/2001/XMLSchema#string

David M Lucas

http://www.w3.org/2001/XMLSchema#string

Louie Naumovski

http://www.w3.org/2001/XMLSchema#string

Margaret S Lucas

http://www.w3.org/2001/XMLSchema#string

Mollie E Moran

http://www.w3.org/2001/XMLSchema#string

Philip S Lecane

http://www.w3.org/2001/XMLSchema#string

Richard A Miller

http://www.w3.org/2001/XMLSchema#string

See-Chun Phan

http://www.w3.org/2001/XMLSchema#string

Thomas S Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase

Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells.

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.

Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.

Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.

P304

1977-1982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428190903288464

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John C Byrd

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19860624

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

phase II clinical trial

lymphocyte